Literature DB >> 23254192

The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Hilal A Lashuel1, Cassia R Overk, Abid Oueslati, Eliezer Masliah.   

Abstract

Disorders characterized by α-synuclein (α-syn) accumulation, Lewy body formation and parkinsonism (and in some cases dementia) are collectively known as Lewy body diseases. The molecular mechanism (or mechanisms) through which α-syn abnormally accumulates and contributes to neurodegeneration in these disorders remains unknown. Here, we provide an overview of current knowledge and prevailing hypotheses regarding the conformational, oligomerization and aggregation states of α-syn and their role in regulating α-syn function in health and disease. Understanding the nature of the various α-syn structures, how they are formed and their relative contributions to α-syn-mediated toxicity may inform future studies aiming to develop therapeutic prevention and intervention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23254192      PMCID: PMC4295774          DOI: 10.1038/nrn3406

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  130 in total

1.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

3.  Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies.

Authors:  He-Jin Lee; Ji-Eun Suk; Christina Patrick; Eun-Jin Bae; Ji-Hoon Cho; Sangchul Rho; Daehee Hwang; Eliezer Masliah; Seung-Jae Lee
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

4.  Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.

Authors:  Katerina E Paleologou; Abid Oueslati; Gideon Shakked; Carla C Rospigliosi; Hai-Young Kim; Gonzalo R Lamberto; Claudio O Fernandez; Adrian Schmid; Fariba Chegini; Wei Ping Gai; Diego Chiappe; Marc Moniatte; Bernard L Schneider; Patrick Aebischer; David Eliezer; Markus Zweckstetter; Eliezer Masliah; Hilal A Lashuel
Journal:  J Neurosci       Date:  2010-03-03       Impact factor: 6.167

5.  Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons.

Authors:  D D Murphy; S M Rueter; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

6.  First appraisal of brain pathology owing to A30P mutant alpha-synuclein.

Authors:  Kay Seidel; Ludger Schöls; Silke Nuber; Elisabeth Petrasch-Parwez; Kristin Gierga; Zbigniew Wszolek; Dennis Dickson; Wei P Gai; Antje Bornemann; Olaf Riess; Abdelhaq Rami; Wilfried F A Den Dunnen; Thomas Deller; Udo Rüb; Rejko Krüger
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

7.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.

Authors:  V N Uversky; J Li; A L Fink
Journal:  J Biol Chem       Date:  2001-09-11       Impact factor: 5.157

8.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

9.  Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.

Authors:  Michael K Lee; Wanda Stirling; Yanqun Xu; Xueying Xu; Dike Qui; Allen S Mandir; Ted M Dawson; Neal G Copeland; Nancy A Jenkins; Don L Price
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

10.  Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.

Authors:  Kevin St P McNaught; Catherine Mytilineou; Ruth Jnobaptiste; Jocelyn Yabut; P Shashidharan; Peter Jennert; C Warren Olanow
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

View more
  541 in total

1.  Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.

Authors:  Jonathan W Werner-Allen; Sarah Monti; Jenna F DuMond; Rodney L Levine; Ad Bax
Journal:  Biochemistry       Date:  2018-02-15       Impact factor: 3.162

Review 2.  The role of Rab GTPases in the pathobiology of Parkinson' disease.

Authors:  Luis Bonet-Ponce; Mark R Cookson
Journal:  Curr Opin Cell Biol       Date:  2019-05-01       Impact factor: 8.382

3.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

4.  Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway.

Authors:  Lei-Lei Chen; Ju-Xian Song; Jia-Hong Lu; Zhen-Wei Yuan; Liang-Feng Liu; Siva Sundara Kumar Durairajan; Min Li
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-13       Impact factor: 4.147

Review 5.  The delta-opioid receptor and Parkinson's disease.

Authors:  Jin-Zhong Huang; Yi Ren; Yuan Xu; Tao Chen; Terry C Xia; Zhuo-Ri Li; Jian-Nong Zhao; Fei Hua; Shi-Ying Sheng; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2018-08-03       Impact factor: 5.243

6.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

7.  Assessment of Cytotoxicity of α-Synuclein in Budding Yeast Using a Spot Growth Assay and Fluorescent Microscopy.

Authors:  Masak Takaine
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study.

Authors:  Wolfgang Singer; Phillip A Low
Journal:  Clin Auton Res       Date:  2015-03-13       Impact factor: 4.435

9.  Untangling alpha synuclein fibrils by graphene quantum dots.

Authors:  Daniel Ysselstein; Dimitri Krainc
Journal:  Mov Disord       Date:  2018-11       Impact factor: 10.338

Review 10.  Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.

Authors:  Sandeep K Sharma; Smriti Priya
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.